Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis

International Journal of Lower Extremity Wounds

Volumn 5, Issue 3, 2006, Pages 213-216

  Tascini, Carlo ^a   Menichetti, F ^a   Gemignani, G ^a   Palumbo, F ^a   Leonildi, A ^a   Tedeschi, A ^a   Piaggesi, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Bactericidal activity; Colistin; Diabetic foot; Imipenem; Osteomyelitis; P aeruginosa; Rifampin; Synergistic activity

Indexed keywords

CEFEPIME; CEFTAZIDIME; COLISTIN; IMIPENEM; RIFAMPICIN;

AGED; ARTICLE; BACTERICIDAL ACTIVITY; CASE REPORT; DEBRIDEMENT; DIABETIC FOOT; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; FOOT AMPUTATION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OSTEOMYELITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; COLISTIN; DIABETIC FOOT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMIPENEM; MALE; METATARSAL BONES; OSTEOMYELITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RIFAMPIN;

EID: 33747063299     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734606291676     Document Type: Article

References (14)

1. Ulbrecht JS, Cavanagh PR, Caputo GM. Foot problems in diabetes: an overview. Clin Infect Dis 2004;39:S73-82.
2. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000;16(Suppl 1):S75-83.
3. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39:S104-14.
4. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-4.
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
6. Clinical and Laboratory Standard Institute (formerly National Committee for Clinical Laboratory Standards). Methodology for the serum bactericidal test. Document M-21A. Villanova (PA): Clinical and Laboratory Standard Institute; 1999.
7. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997;41:881-5.
8. Tascini C, Tagliaferri E, Iapoce R, Leonildi A, Menichetti F. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive Aspergillosis in humans, with a method to test ex vivo synergism. Clin Microbiol Infect 2003;9:901-2.
9. Tascini C, Gemignani G, Leonildi A, Menichetti F. Ex vivo synergism: a method for optimizing antimicrobial combinations for difficult-to-treat enterococcal endocarditis. J Chemother 2003;15:613-15.
10. Paterson D, Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis 2000;31:1119-25.
11. Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004:16;282-7.
12. Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin and amikacin against a multi resistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 2000;6:690-1.
13. Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55:954-7.
14. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, et al. Combined colistin and rifampin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-3.